Translations:Ipragliflozin/6/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 21:00, 20 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Ipragliflozin)
'''Ipragliflozin''' ([[International nonproprietary name|INN]], trade names '''Suglat''') is a pharmaceutical drug for treatment of [[Diabetes mellitus type 2|type 2 diabetes]]. Ipragliflozin, jointly developed by [[Astellas Pharma]] and Kotobuki Pharmaceutical, was approved in [[Japan]] on January 17, 2014, and in [[Russia]] on May 22, 2019.

Ipragliflozin (INN, trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, and in Russia on May 22, 2019.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Ipragliflozin/6/en&oldid=118274"